LARIMAR THERAPEUTICS, INC. Long-Term Debt, Maturity, Year Four
LARIMAR THERAPEUTICS, INC. (LRMR) had Long-Term Debt, Maturity, Year Four of $7.27 million as of 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour · last filed 2018-11-09
- 2018-09-30: Long-Term Debt, Maturity, Year Four $7.27M.
- 2018-06-30: Long-Term Debt, Maturity, Year Four $7.27M.
- 2018-03-31: Long-Term Debt, Maturity, Year Four $7.27M.
- 2017-12-31: Long-Term Debt, Maturity, Year Four $7.27M.
| Period end | Long-Term Debt, Maturity, Year Four |
|---|---|
| 2018-09-30 | $7.27M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $7.27M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $7.27M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $7.27M 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |